Litcius/Paper detail

Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice

Siwei Wang, Tian Lan, Hangfei Chen, Hao Sheng, Chun-yi Xu, Lifeng Xu, Fang Zheng, Feng Zhang

2022Frontiers in Pharmacology16 citationsDOIOpen Access PDF

Abstract

NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient C. elegans , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.

Topics & Concepts

AMPKLimoninActivator (genetics)ChemistryLipid metabolismFatty liverPharmacologyEndocrinologyInternal medicineBiochemistryMedicineDiseaseEnzymeProtein kinase AReceptorPancreatic function and diabetesDiet, Metabolism, and DiseaseNatural Antidiabetic Agents Studies
Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice | Litcius